Literature DB >> 27834580

NKG2D ligand expression in pediatric brain tumors.

Kristen Haberthur1, Kathryn Brennan2, Virginia Hoglund1, Stephanie Balcaitis1, Harrison Chinn1, Amira Davis1, Shannon Kreuser1, Conrad Winter3, Sarah E S Leary4, Gail H Deutsch5, Richard G Ellenbogen6, Courtney A Crane1,7.   

Abstract

Adult brain tumors establish an immunosuppressive tumor microenvironment as a modality of immune escape, with several immunotherapies designed to overcome this barrier. However, the relationship between tumor cells and immune cells in pediatric brain tumor patients is not as well-defined. In this study, we sought to determine whether the model of immune escape observed in adult brain tumors is reflected in patients with pediatric brain tumors by evaluating NKG2D ligand expression on tissue microarrays created from patients with a variety of childhood brain tumor diagnoses, and infiltration of Natural Killer and myeloid cells. We noted a disparity between mRNA and protein expression for the 8 known NKG2D ligands. Surprisingly, high-grade gliomas did not have increased NKG2D ligand expression compared to normal adjacent brain tissue, nor did they have significant myeloid or NK cell infiltration. These data suggest that pediatric brain tumors have reduced NK cell-mediated immune surveillance, and a less immunosuppressive tumor microenvironment as compared to their adult counterparts. These data indicate that therapies aimed to improve NK cell trafficking and functions in pediatric brain tumors may have a greater impact on anti-tumor immune responses and patient survival, with fewer obstacles to overcome.

Entities:  

Keywords:  Immune privilege; NK cells; NKG2D ligands; immune surveillance; immunosuppressive

Mesh:

Substances:

Year:  2016        PMID: 27834580      PMCID: PMC5199167          DOI: 10.1080/15384047.2016.1250047

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  74 in total

1.  Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Authors:  Cédric Ménard; Jean-Yves Blay; Christophe Borg; Stefan Michiels; François Ghiringhelli; Caroline Robert; Céline Nonn; Nathalie Chaput; Julien Taïeb; Nicolas F Delahaye; Caroline Flament; Jean-François Emile; Axel Le Cesne; Laurence Zitvogel
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 2.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

3.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Authors:  Courtney A Crane; Seunggu J Han; Jeffery J Barry; Brian J Ahn; Lewis L Lanier; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2009-11-05       Impact factor: 12.300

4.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Peter M de Blank; Carol Kruchko; Claire M Petersen; Peter Liao; Jonathan L Finlay; Duncan S Stearns; Johannes E Wolff; Yingli Wolinsky; John J Letterio; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-01       Impact factor: 12.300

Review 5.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

7.  The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children.

Authors:  Nicolas R Smoll; Katharine J Drummond
Journal:  J Clin Neurosci       Date:  2012-09-13       Impact factor: 1.961

8.  Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.

Authors:  Pascale André; Roberta Castriconi; Marion Espéli; Nicolas Anfossi; Tiffany Juarez; Sophie Hue; Holli Conway; François Romagné; Alessandra Dondero; Marina Nanni; Sophie Caillat-Zucman; David H Raulet; Cristina Bottino; Eric Vivier; Alessandro Moretta; Pascale Paul
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

9.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

Authors:  Paula Codo; Michael Weller; Gunter Meister; Emese Szabo; Alexander Steinle; Marietta Wolter; Guido Reifenberger; Patrick Roth
Journal:  Oncotarget       Date:  2014-09-15

10.  Immunotherapeutic implications of the immunophenotype of pediatric brain tumors.

Authors:  Andrea M Griesinger; Andrew M Donson; Nicholas K Foreman
Journal:  Oncoimmunology       Date:  2014-01-01       Impact factor: 8.110

View more
  11 in total

1.  Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.

Authors:  Cavan P Bailey; Mary Figueroa; Achintyan Gangadharan; Yanwen Yang; Megan M Romero; Bridget A Kennis; Sridevi Yadavilli; Verlene Henry; Tiara Collier; Michelle Monje; Dean A Lee; Linghua Wang; Javad Nazarian; Vidya Gopalakrishnan; Wafik Zaky; Oren J Becher; Joya Chandra
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

Review 2.  Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities.

Authors:  Rosy Njonkou; Christopher M Jackson; Graeme F Woodworth; David S Hersh
Journal:  Cancer Immunol Immunother       Date:  2022-01-12       Impact factor: 6.630

3.  Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.

Authors:  Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 4.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29

5.  Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.

Authors:  Nicole A P Lieberman; Kole DeGolier; Heather M Kovar; Amira Davis; Virginia Hoglund; Jeffrey Stevens; Conrad Winter; Gail Deutsch; Scott N Furlan; Nicholas A Vitanza; Sarah E S Leary; Courtney A Crane
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

6.  Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma.

Authors:  Grant L Lin; Surya Nagaraja; Mariella G Filbin; Mario L Suvà; Hannes Vogel; Michelle Monje
Journal:  Acta Neuropathol Commun       Date:  2018-06-28       Impact factor: 7.801

Review 7.  Natural Killer Cells: Tumor Surveillance and Signaling.

Authors:  Lizeth G Meza Guzman; Narelle Keating; Sandra E Nicholson
Journal:  Cancers (Basel)       Date:  2020-04-11       Impact factor: 6.639

Review 8.  CAR T Cell Therapy for Pediatric Brain Tumors.

Authors:  John D Patterson; Jeffrey C Henson; Rebecca O Breese; Kevin J Bielamowicz; Analiz Rodriguez
Journal:  Front Oncol       Date:  2020-08-12       Impact factor: 6.244

9.  Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8+ T-Cell Behaviors.

Authors:  Ana Carmena Moratalla; Yves Carpentier Solorio; Florent Lemaitre; Negar Farzam-Kia; Annie Levert; Stephanie E J Zandee; Boaz Lahav; Jean Victor Guimond; Elie Haddad; Marc Girard; Pierre Duquette; Catherine Larochelle; Alexandre Prat; Nathalie Arbour
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-12-06

Review 10.  The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.

Authors:  Miriam Santiago Kimpo; Bernice Oh; Shawn Lee
Journal:  Curr Oncol Rep       Date:  2019-09-10       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.